Dhierin is a leading contributor covering the aerospace industry on Seeking Alpha. With his Aerospace Engineering background he has a more indepth knowledge about aerospace products, so most of his articles will be about companies in the aerospace industry or airline industry, comparing products and looking at market forecasts providing investors with unique and thorough insights.
Dhierin has accumulated over 4,000,000 views never failing to spark healthy and thoughtful discussions for investors and aerospace professionals.
AeroAnalysis offers wide variety of services, ranging from providing data and cost models to consultancy possibilities. Check out our website for more information.
HIT THE FOLLOW TAB AND KEEP UP WITH ALL OF OUR ARTICLES! and Remember To
“Never Give Up, Never Ever Give Up”
MBA MIT Sloan, BS/MS in Electrical and Computer Engineering Worcester Polytechnic Institute. Technology startup veteran. Travel Enthusiast: Shanghai, Kyoto, Tokyo, Osaka, Taipei, Hong Kong, Tasmania, Sydney, Melbourne, Ephesus, Istanbul, Athens, Barcelona, Monaco, London, Naples, Pompei, Rome, Scotland, Amsterdam, and my all time favorite, the British Virgin Islands. My Dad got me into the WSJ at age 12 and I've been hooked ever since.
2nd Market Capital Advisory specializes in the analysis and trading of real estate securities. Through a selective process and consideration of market dynamics, we aim to construct portfolios for rising streams of dividend income and capital appreciation.I am an investment adviser representative of 2nd Market Capital Advisory Corporation.
I began investing in 2006, without any real inkling to what I was doing. Now a decade in, I've got some momentum and I'm excited to share my findings and opinions here on Seeking Alpha with you -- my audience. I may not always be right, but of course that goes for any analyst. But my promise is to take each article as an opportunity to improve from my last.
I'm convinced that investing in great companies is the best way to create long-term wealth. It's a shame that I see many of my peers of the millennial generation stay away from stocks just because they fear the unknown. Let's work together to demystify stocks.
A couple of my favorite financial quotes:
"In all toil there is profit, but mere talk tends only to poverty." - Proverbs 14:23
"Where there are no oxen, the manger is clean, but abundant crops come by the strength of the ox." - Proverbs 14:4
I run my own private equity fund. My returns have averaged 25+ percent and I have outperformed the S&P 500 by at least 10 points every year. I take high conviction positions, as well engaging in special situation investing-risk arbitrage, liquidations and corporate restructurings.
Brian is the founder of Investor in the Family and DIY Investing Summit.
At Investor in the Family (http://investorinthefamily.com/), Brian's goal is to help protect investors from making big mistakes that jeopardize their portfolios and financial futures.
The DIY Investing Summit (http://diyinvestingsummit.com/) was created to help link self-directed investors with carefully filtered and proven investing professionals to help save investors both time and money while building a portfolio that outperforms.
If you'd like to connect or learn more, please feel free to send a private message via Seeking Alpha platform.
Hedgeye Risk Management is an independent investment research and online financial media firm. Focused exclusively on generating and delivering thoughtful investment ideas in a proven buy-side process, the firm combines quantitative, bottom-up and macro analysis with an emphasis on timing.
The Hedgeye team features some of the world's most regarded research analysts - united around a vision of independent, un-compromised real-time investment research as a service. We measure ourselves on our core values: Transparency, Accountability, and Trust.
Stephen Simpson, CFA, is a freelance financial writer and investor.
I have worked for both sell-side and buy-side firms (equities and fixed income), with the largest percentage of my working time spent in med-tech. At this point I am now effectively in a "working retirement".
I write because I find that the process helps me take better notes, be more disciplined about modeling, and come up with a more coherent investment view for my portfolio management needs. If I'm writing about a stock, it's generally because I'm interested in it as an investment prospect or I think there's an interesting story to tell.
I don't share my models, so please don't ask.
More of my writings can be found at my blog Kratisto Investing (kratistoinvesting.blogspot.com), or Twitter (@Kratisto_Invest).
Robert has worked in Corporate America for 25 years in various technical roles including Information Technology, Audit, and Information Security & Assurance. During the time he was building a career and raising a family, he earned a Masters Degree in Information Assurance from a well respected, private military school.
In addition, Robert founded, directed, and sold a real estate investment company in the Texas market. Robert still holds a selection of properties in his private portfolio, though he does not manage real estate for others any longer.
Robert has also, throughout his career, held sales and support positions in Forex and other securities companies, along the way passing the Series 3, 6, 63, and 7 investment advisory exams. Robert is not professionally active in these roles currently, does not sell securities, and does not manage investments for others. All published articles are intended to be used for research and idea generation purposes only.
We are looking to create actionable ideas and insights into equity markets. More importantly, we are focused on learning from other seasoned investors and tweaking our strategy to best position ourselves for long term value creation. We always welcome critiques on our investment style and we hope to post ideas our readers can resonate with and have meaningful discussions on. Shehryar Khursheed is a freshman at The Wharton School at the University of Pennsylvania and is tailoring his higher education to develop skills that will provide insight into value investing. Shahkar Khursheed is a junior at The McCombs School of Business at the University of Texas at Austin and is majoring in Finance with a focus on investment management and is pursuing a minor in financial accounting.
Top 100 Blogger According to TipRanks
Years of experience working for a registered independent advisor ("RIA"), structuring client accounts, performing due diligence on separately managed accounts, and performing fixed income and equity research. Worked at a bulge bracket investment bank on the trading desk for mortgage-backed securities ("MBS") as well as within derivatives trading, finished my time there in internal risk and audit.
Now invest and write full time on Seeking Alpha.
I am an individual investor and focus on investing in dividend-paying and dividend-growing stocks with a long-term horizon. In addition to a DGI portfolio, I manage and invest in a couple of high-income portfolios as well as some Risk-adjusted Rotation Strategies. I believe "Passive Income" is what makes you 'Financially Free'. My personal goal is to generate at least 50% of my retirement income from dividends and rest from other investments like real-estate (rental) etc. I have been investing for the last 25 years and consider myself an experienced investor. I plan to share my experiences by way of writing two or three articles a month and also share my portfolio strategy.
I am currently long on ABT, ABBV, JNJ, PFE, NVS, NVO, CL, CLX, GIS, UL, NSRGY, PG, MON, ADM, MO, PM, KO, DEO, MCD, WMT, WBA, CVS, LOW, CSCO, MSFT, INTC, T, VZ, VTR, CVX, XOM, VLO, HCP, O, OHI, NNN, STAG, WPC, MAIN, NLY, ARCC, PCI, PDI, PFF, RFI, RNP, UTF, EVT, FFC, HQH, KYN, NMZ, NBB, JPS, JRI, TLT.
- Both idealistic and practical.
- Believe that creating excellent outcomes requires setting ambitious goals and applying my understanding of how the world works to achieve them.
- SA PRO Managing Editor Recognition: https://seekingalpha.com/article/4168521-editors-notes-jd-com-spotlight-couple-takeover-targets
As an individual investor nearing retirement I am trying to build my financial assets in order to have a fulfilling retirement. I am interested in trading both long and short; or at least using inverse ETFs, to take advantage of market declines. Having long term and short term trading strategies, proper execution of my trading plan, and absolute investing results are my goals. I see my articles as a way to keep me focused on developing winning trades. I also expect to learn much from the feedback that is provided in the comments section.
We are a collaboration of biotechnology insights providing investment research. Currently, we are featuring our Lucky Seven swing-trading portfolio of biotechnology stocks that present with excellent short-term risk-to-reward ratios. Unlike nearly all other services, we 1. do not overwhelm you with dozens of picks to choose from; 2. give you our top three picks; 3. consider time as money too, because it is; 4. organize our picks in a manner that reflects individual risk-tolerance; 5. hold ourselves accountable for each recommendation by keeping track of all of our trades; 6. provide insight as to when to enter a ticker and when to exit (timing is everything in biotech investing). We will also occasionally present long-term ideas, research, technical analysis, etc. At the helm of Clover is Stephen Ayers. He is a Registered Nurse who works on an intermediate care unit in a hospital and witnesses first-hand the powerful impact of medicine. He is an avid biotechnology researcher and advocater. He believes collaboration with persons of differing biotechnology angles will enrich his work. Subsequently, he has formed Clover Biotech Research to provide a platform for investors to experience several different perspectives. Clover recently welcomed Gobinath Varadappan, a biomedical engineer with big pharma experience and knowledge of clinical, regulatory, and commercial aspects of drug development. Gobinath is looking forward to making vital contributions to the team. Clover plans to secure additional advisers and writers in the future.
Brad Thomas is a research analyst and he currently writes weekly for Forbes and Seeking Alpha where he maintains research on many publicly-listed REITs. In addition, Thomas is the Editor of the Forbes Real Estate Investor, a monthly subscription-based newsletter.
Thomas has also been featured in Forbes Magazine, Kiplinger’s, US News & World Report, Money, NPR, Institutional Investor, GlobeStreet, CNN, Newsmax, and Fox. He is the #1 contributing analyst on Seeking Alpha in 2014, 2015, 2016, and 2017 (based on page views).
Thomas has co-authored a book, The Intelligent REIT Investor, and is the author of The Trump Factor: Unlocking The Secrets Behind The Trump Empire (available on Amazon).
Thomas received a Bachelor of Science degree in Business/Economics from Presbyterian College and he is married with 5 wonderful kids.
I am the Founder of Biotech Analysis Central, A subscription service on Seeking Alpha's Marketplace. If you want to learn more about biotech investing or you want to check out my biotech analysis you can do so with a free 2-week trial to my service. Just hit the "Learn More" button on the bottom of the Marketplace Research Tab. I have a Bachelors of Applied Science Degree In Technology Management, Industrial and Business Services Management from St. Petersburg College Florida. I have been investing in biotech stocks for many years, and I prefer to invest as a long term investor. With that In mind I seek stocks that have long term value! I primarily Like to Invest In biotechnology stocks and I accept the risks. I Write for the Healthcare Sector and Stock market in general. I contribute to Seeking Alpha, Talk Markets, and CNA Finance. I run my own biotechnology website Biotechpicklist.com
You can follow me on stocktwits.com under the name BiopharmaPro where I currently have (60,043) followers. Join me in my quest to find the best biotechnology stocks that deliver results to help patients with new treatment options. I am not afraid to find some biotech stocks to short either after results have proven a drug to be ineffective. Looking at both the negative and positive aspects of biotech investing is the best way to invest in this sector.
Seeking Alpha PRO is our premium service for serious investors.
PRO subscribers receive early access to our best long or short ideas - 20-30 articles a week, as selected by our PRO editorial team. They also receive exclusive access to our archive of over 15,000 professional level ideas and research, focused primarily on single equity articles.
We will use this account to publish announcements related to PRO, as well as our PRO Weekly Digest, a new series that will be made available first to PRO subscribers but then to all readers interested in learning about PRO or reading ideas from some of our top authors.
If you're interested in PRO, check out this page for more details. If you'd like to get in touch with our sales team, contact proaccess at seekingalpha.com, and if you'd like to reach our editorial team, write to pro-editors at seekingalpha.com.
I manage a conservative portfolio of blue-chip equities. I target dividend-paying blue chips on sale. The majority of my articles will focus on what I know best (and what is under-covered on Seeking Alpha), Canadian mid and large caps. REITs are my focus, though I dabble in everything. Ranked 3rd on Seeking Alpha for Services stocks!
To get notified when I release a new article simply hit the orange follow button above!
Connect with me on Twitter!
Sramana Mitra is the founder of One Million by One Million (1M/1M), a global virtual accelerator that aims to help one million entrepreneurs globally to reach $1 million in revenue and beyond. She is a Silicon Valley entrepreneur and strategy consultant, she writes the blog Sramana Mitra On Strategy, and is author of the Entrepreneur Journeys book series and Vision India 2020. From 2008 to 2010, Mitra was a columnist for Forbes. As an entrepreneur CEO, she ran three companies: DAIS, Intarka, and Uuma. Sramana has a master’s degree in electrical engineering and computer science from the Massachusetts Institute of Technology. Full bio can be found at http://www.sramanamitra.com/bio/
I am a biotech investor with a PhD in Biochemistry and Molecular Biology. I hope to provide a crucial piece of total due diligence as well as interesting insight into clinical findings that may impact readers' portfolios and lives.
I also collaborate with Avisol Capital Partners on their Marketplace service known as the Total Pharma Tracker (TPT). Some of my work will be available to TPT subscribers either exclusively, or in advance. If you are interested, please click the link above!
Investor/trader looking for under appreciated stocks in strong performing sectors. Strong belief in using medium to long-term trends and recognizing low risk investments to increase odds of portfolio out-performance. High focus on the next wave of the technological revolution - automation, machine learning, and convenient consumerism. Will use discounted cash flows, macro trends and the current stage of the business cycle to recognize pockets of opportunities in the market. "A rising tide lifts all boats".. and some boats more than most
Leadership in Investment Banking and Capital Markets at Merrill Lynch in Europe and Asia Pacific.
One of the founders of the Financial Instituition Capital Securities Market.
Successful private investor in bank capital and equity instruments.
Andrew Left's Citron Research (http://www.citronresearch.com/) (formally known as Stocklemon.com) seeks to expose companies whose management is in some way misleading investors. Left digs into SEC filings, financials, management histories and other data to uncover such situations, and he is usually short the stocks he writes about. Mr. Left has been publishing for 7 years and has created a track record that is unrivaled in short selling. Mr. Left has been cited in Barron's, Wall St Journal, CNBC and other major publications repeatedly for his work. Mr. Left was also an invited speaker at the reknown Master Investor Conference.
Visit: Citron Research (http://www.citronresearch.com/)
I seek to liberate investors from the chains of borrowed opinions by teaching metric awareness that leads to the formation of your own opinions. I am a retail investor that gathers, processes and analyzes significantly more data than average. I share that data in my articles. I let the data do the talking. I am only taking dictation as the data tells its message.
I am a former hedge fund portfolio manager that trades for my own personal account. I espouse Graham and Dodd/Buffett style investing, always on the lookout for value equities or bonds. A graduate of Northwestern's Kellogg School of Management, I lived in NYC for a decade before relocating with my family to the Charlotte, NC area.